RecruitingNCT07459257

Psychiatric Symptom Predictors in Methamphetamine-Induced Psychosis

Investigation of Factors Associated With Psychiatric Symptoms in Methamphetamine-Induced Psychotic Disorder: One-Year Longitudinal Study


Sponsor

Elazığ Mental Health and Diseases Hospital

Enrollment

150 participants

Start Date

Feb 3, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This longitudinal observational study aimed to investigate environmental, familial, and individual factors associated with psychiatric symptom severity in participants diagnosed with methamphetamine-induced psychotic disorder (MP). Participants diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5-TR) criteria was followed/will be followed prospectively for one year. Sociodemographic characteristics, treatment adherence, perceived social support, addiction-related clinical variables, insight levels, and psychotic symptoms was assessed/will be assessed monthly using standardized psychometric instruments. The study aimed to identify predictors associated with relapse-remission patterns and changes in psychiatric symptoms over a one-year follow-up period.


Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study investigates why some people who develop psychosis after using methamphetamine (a stimulant drug) continue to have psychiatric symptoms while others recover. Researchers want to find clinical and biological markers that can predict who is most at risk of ongoing psychiatric illness. **You may be eligible if...** - You are between 18 and 64 years old - You have been diagnosed with methamphetamine-induced psychotic disorder (a condition where methamphetamine use triggered psychosis, such as hallucinations or paranoia) - You have not taken any psychiatric medications for at least one month before admission - You are able to give informed consent **You may NOT be eligible if...** - You have high blood pressure, diabetes, chronic kidney disease, or rheumatoid arthritis - You have a heart condition, lupus, or other serious immune or neurological condition - You have a primary psychiatric disorder (like schizophrenia) that is not related to methamphetamine - You have an alcohol use disorder Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Elazığ Mental Health and Diseases Hospital

Elâzığ, Elâzığ, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07459257


Related Trials